SterisCare Pharma is set to embark on an ambitious growth strategy for FY 2026-27, with a Rs 50 Crore capital expenditure plan that includes the commissioning of a third manufacturing block, expansion into four new export territories, and a proposed Initial Public Offering (IPO).

Expansion Highlights

• New manufacturing block with capacity of 1.8 billion tablets per annum
• Entry into UAE, Kenya, Tanzania, and Sri Lanka markets
• R&D investment doubled to Rs 8 Crore for FY2026-27
• Digital transformation initiative across supply chain and CRM

IPO Plans

The company is in preliminary discussions with merchant bankers and is targeting a main-board listing on BSE and NSE by Q3 FY2026-27, subject to regulatory approvals. The IPO proceeds will primarily fund working capital requirements and repay existing term loans.

Financial Highlights (FY 2025-26)

Metric	Value
Revenue	Rs 218 Crore
EBITDA	Rs 41 Crore (18.8%)
PAT	Rs 22 Crore
Export Revenue	Rs 34 Crore (15.6% of total)